Alan Fuhrman's Insider Trades & SAST Disclosures
Alan Fuhrman's most recent trade in SpringWorks Therapeutics Inc was a trade of 10,060 Common Stock done . Disclosure was reported to the exchange on May 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Alan Fuhrman.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 10,060 | 24,727 (0%) | 0% | 0 | Common Stock | |
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 9.77 per share. | 14 Mar 2025 | 1,238 | 14,087 | - | 9.8 | 12,101 | Common Stock |
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 30 Oct 2024 | 9,500 | 12,849 | - | 16.0 | 151,954 | Common Stock |
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 12.48 per share. | 13 Sep 2024 | 954 | 3,349 | - | 12.5 | 11,904 | Common Stock |
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2024 | 115,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| Esperion Therapeutics Inc. | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 32,500 | 32,500 | - | - | Stock Option (right to buy) | |
| Esperion Therapeutics Inc. | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 23,000 | 53,404 (0%) | 0% | 0 | Common Stock | |
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 12,216 | 12,216 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 4,095 | 14,667 (0%) | 0% | 0 | Common Stock | |
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 12.48 per share. | 15 Mar 2024 | 932 | 2,395 | - | 12.5 | 11,629 | Common Stock |
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2023 | 62,685 | 62,685 | - | - | Stock Option (Right to Buy) | |
| Esperion Therapeutics Inc. | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Esperion Therapeutics Inc. | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 5,150 | 30,404 (0%) | 0% | 0 | Common Stock | |
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 13,774 | 13,774 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 4,648 | 10,572 (0%) | 0% | 0 | Common Stock | |
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 328,000 | 328,000 | - | - | Stock Option (Right to Buy) | |
| Tyra Biosciences Inc | Alan Fuhrman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 32,800 | 32,800 | - | - | Stock Option (Right to Buy) | |
| Esperion Therapeutics Inc. | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 15,318 | 15,318 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 4,818 | 5,924 (0%) | 0% | 0 | Common Stock | |
| Esperion Therapeutics Inc. | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 12,376 | 25,254 (0%) | 0% | 0 | Common Stock | |
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 6,998 | 6,998 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 1,106 | 25,227 (0%) | 0% | 0 | Common Stock | |
| Esperion Therapeutics Inc. | Alan Fuhrman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 1,221 | 12,878 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges